We are live on ! Find out more
49.13 USD
-0.38
0.77%
At close Updated Nov 2, 4:00 PM EST
Pre-market
After hours
49.27
+0.14
0.28%
1 day
-0.77%
5 days
-3.29%
1 month
4.47%
3 months
-4.62%
6 months
-3.48%
Year to date
-1.01%
1 year
6%
5 years
-8.17%
10 years
-0.47%
 

About: In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Employees: 66,841

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 58.8%
Neutral 29.4%
Negative 11.8%
Positive
Seeking Alpha
4 days ago
GSK: The Gas Pedal Is Still Down, But Bumps Ahead
Despite the Q3 disappointments, I maintain my Buy rating, as strong Specialty Medicines growth and improving pipeline momentum continue to support GSK's long-term ambitions. Specialty Medicines revenue rose 14%, helping offset weakness in Vaccines. HIV, Oncology and Respiratory remain key drivers of GSK's future growth. The vaccine business underperformed, with Shingrix and Arexvy missing expectations; management attributes this to China inventory reductions and broader RSV demand issues.
GSK: The Gas Pedal Is Still Down, But Bumps Ahead
Positive
Zacks Investment Research
4 days ago
GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?
GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.
GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?
Neutral
Seeking Alpha
5 days ago
GSK plc (GSK) Q3 2026 Earnings Call Transcript
GSK plc ( GSK ) Q3 2026 Earnings Call October 28, 2026 8:00 AM EDT Company Participants Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations Luke Miels - CEO & Director Tony Wood - Chief Scientific Officer and Head of R&D Nina Mojas - President of Global Product Strategy Julie Brown - CFO & Executive Director David Redfern - President of Corporate Development Conference Call Participants James Gordon - Barclays Bank PLC, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Michael Leuchten - Jefferies LLC, Research Division Kerry Holford - Joh. Berenberg, Gossler & Co. KG, Research Division Sachin Jain - BofA Securities, Research Division Zain Ebrahim - JPMorgan Chase & Co, Research Division Matthew Weston - UBS Investment Bank, Research Division Graham Glyn Parry - Citigroup Inc., Research Division Trung Huynh - RBC Capital Markets, Research Division Presentation Jeff McLaughlin VP of Investor Relations & Interim Head of Investor Relations Welcome, everyone, and thanks for joining GSK's Q3 2026 results.
GSK plc (GSK) Q3 2026 Earnings Call Transcript
Positive
MarketBeat
5 days ago
What GSK (GSK) Said on Its Q3 Earnings Call
GSK NYSE: GSK reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, supported by specialty medicines, new product launches and oncology growth. Core operating profit increased 5%, while core earnings per share rose 1%.
What GSK (GSK) Said on Its Q3 Earnings Call
Neutral
Zacks Investment Research
5 days ago
GSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines Sales
GSK's Q3 earnings beat estimates as HIV, oncology and respiratory medicines drive revenue growth, while declining vaccine sales weigh on shares.
GSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines Sales
Positive
Benzinga
5 days ago
GSK's Specialty Drugs Grow by Double Digits While Vaccines Slip in a Q3 Beat
GSK Plc (NYSE:GSK) reported third-quarter adjusted earnings of $1.47 per share (54.6 pence), beating the analyst consensus estimate of $1.40.
GSK's Specialty Drugs Grow by Double Digits While Vaccines Slip in a Q3 Beat
Positive
Seeking Alpha
5 days ago
GSK: Why I'm Still Bullish After Strong Q3 Results
GSK plc delivered strong results today. In the third quarter, revenue and non-GAAP EPS grew 5.7% and 8.2% quarter-on-quarter, respectively. Cabenuva, GSK's long-acting HIV treatment, generated $641 million in sales, up 35.2% year over year.
GSK: Why I'm Still Bullish After Strong Q3 Results
Negative
Investors Business Daily
5 days ago
GSK Tumbles As Vaccine Sales Dip, Dragging On Topline Beat
GSK stock toppled early Wednesday after the company's third-quarter vaccine sales fell short, outshining a solid topline.
GSK Tumbles As Vaccine Sales Dip, Dragging On Topline Beat
Positive
Zacks Investment Research
5 days ago
GSK (GSK) Q3 Earnings and Revenues Beat Estimates
GSK (GSK) came out with quarterly earnings of $1.47 per share, beating the Zacks Consensus Estimate of $1.4 per share. This compares to earnings of $1.48 per share a year ago.
GSK (GSK) Q3 Earnings and Revenues Beat Estimates
Positive
WSJ
6 days ago
GSK Sales Get Boost From Specialty Medicines
The U.K. drugmaker's strength in the segment allowed it to offset a declining vaccines revenue and a flat performance in general medicines.
GSK Sales Get Boost From Specialty Medicines
Price charts implemented using Lightweight Charts™